8.43
0.16 (1.93%)
| Penutupan Terdahulu | 8.27 |
| Buka | 8.21 |
| Jumlah Dagangan | 5,595,717 |
| Purata Dagangan (3B) | 8,657,500 |
| Modal Pasaran | 2,890,085,888 |
| Harga / Jualan (P/S) | 75.08 |
| Harga / Buku (P/B) | 6.22 |
| Julat 52 Minggu | |
| Tarikh Pendapatan | 3 Nov 2025 |
| Margin Operasi (TTM) | -1,913.23% |
| EPS Cair (TTM) | -2.20 |
| Jumlah Hutang/Ekuiti (D/E MRQ) | 2.72% |
| Nisbah Semasa (MRQ) | 9.01 |
| Aliran Tunai Operasi (OCF TTM) | -157.34 M |
| Aliran Tunai Bebas Leveraj (LFCF TTM) | -64.76 M |
| Pulangan Atas Aset (ROA TTM) | -23.33% |
| Pulangan Atas Ekuiti (ROE TTM) | -119.66% |
Arah Aliran Pasaran
| Jangka Pendek | Jangka Sederhana | ||
| Industri | Biotechnology (US) | Menaik | Bercampur |
| Biotechnology (Global) | Menaik | Bercampur | |
| Stok | Nuvation Bio Inc. | Menaik | Menaik |
AISkor Stockmoo
| Konsensus Penganalisis | 1.5 |
| Aktiviti Orang Dalam | NA |
| Volatiliti Harga | -5.0 |
| Purata Bergerak Teknikal | 2.5 |
| Osilator Teknikal | -0.5 |
| Purata | -0.38 |
|
Nuvation Bio Inc is a biopharmaceutical company tackling unmet needs in oncology by developing differentiated and novel therapeutic candidates. Its product candidate, taletrectinib, is an oral, potent, central nervous system-active, selective, next-generation c-ros oncogene 1 (ROS1) inhibitor specifically designed for the treatment of patients with ROS1+ non-small cell lung cancer (NSCLC). In addition, its clinical-stage pipeline includes differentiated, novel oncology product candidates such as Safusidenib, NUV-1511, and NUV-868 in their different stages of development. The company generates revenue through out-licensing collaborative agreements with its customers located in China and Japan. |
|
| Sektor | Healthcare |
| Industri | Biotechnology |
| Gaya Pelaburan | Small Value |
| % Dimiliki oleh Orang Dalam | 19.14% |
| % Dimiliki oleh Institusi | 62.26% |
Pemilikan
| Nama | Tarikh | Syer Dipegang |
|---|---|---|
| Decheng Capital Llc | 30 Sep 2025 | 25,954,439 |
| Laurion Capital Management Lp | 30 Sep 2025 | 9,705,532 |
| Omega Fund Management, Llc | 30 Sep 2025 | 8,831,089 |
| Aisling Capital Management Lp | 30 Sep 2025 | 2,960,659 |
| Julat 52 Minggu | ||
| Julat Harga Sasaran | ||
| Tinggi | 17.00 (HC Wainwright & Co., 101.66%) | Beli |
| Median | 12.00 (42.35%) | |
| Rendah | 7.00 (UBS, -16.96%) | Pegang |
| Purata | 12.00 (42.35%) | |
| Jumlah | 3 Beli, 1 Pegang | |
| Harga Purata @ Panggilan | 5.22 | |
| Syarikat | Tarikh | Harga Sasaran | Panggilan | Harga @ Panggilan |
|---|---|---|---|---|
| RBC Capital | 03 Mar 2026 | 13.00 (54.21%) | Beli | 4.36 |
| 21 Jan 2026 | 12.00 (42.35%) | Beli | 6.15 | |
| UBS | 03 Mar 2026 | 7.00 (-16.96%) | Pegang | 4.36 |
| 07 Jan 2026 | 10.00 (18.62%) | Pegang | 8.84 | |
| Wedbush | 10 Feb 2026 | 11.00 (30.49%) | Beli | 5.71 |
| HC Wainwright & Co. | 12 Jan 2026 | 17.00 (101.66%) | Beli | 6.46 |
Tiada data dalam julat masa ini.
Tahap sokongan, rintangan dan garis aliran yang dibentangkan telah dihasilkan oleh model kecerdasan buatan (AI) dan harus ditafsirkan dengan berhati-hati.
Portfolio
| Keuntungan Nyata | - |
| Keuntungan Tidak Nyata | - |
| Dividen Diterima 2026 | - |
| Jumlah Untung | - |
| Pulangan Purata | - |
| Kuantiti (Beli) | - |
| Purata Harga (Beli) | - |
| Kuantiti (Jual) | - |
| Purata Harga (Jual) | - |